SATB2 and neoplasm: Despite consensus on the highly specific expression of SATB2 in CRC, in contrast to other types of neoplasms, only a few authors tried to semi-quantitatively, i.e., by applying a scoring system, evaluate the intensity and range of immunoreactivity in the CRC samples in regard to patients’ clinicopathological characteristics.